<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03412734</url>
  </required_header>
  <id_info>
    <org_study_id>17-102</org_study_id>
    <nct_id>NCT03412734</nct_id>
  </id_info>
  <brief_title>Vaginal Preparation Prior to Hysterectomy</brief_title>
  <official_title>Is Chlorhexidine Vaginal Preparation Prior to Hysterectomy Superior to Iodine in Reducing Bacterial Count; a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TriHealth Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TriHealth Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized controlled trial to determine the influence of chlorhexidine gluconate&#xD;
      surgical/topical antiseptic solutions on the bacterial environment of the vagina during&#xD;
      hysterectomy and compare that to the effect of standard iodine-based preparations on the&#xD;
      same.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Postoperative infection remains the most common complication of surgical procedures in&#xD;
      gynecology. Historically, 30-40% of patients undergoing a hysterectomy develop a&#xD;
      post-operative infection. The initiation of antibiotic prophylaxis for appropriate surgical&#xD;
      procedures was a significant advancement in the prevention of surgical site infection.&#xD;
&#xD;
      Antibiotic prophylaxis has been standardized and universally implemented. A remaining&#xD;
      variable is the method of aseptic preparation of the vagina with substantial variation of&#xD;
      technique being reported even within institutions.&#xD;
&#xD;
      The most recent Committee Opinion by the American College of Obstetricians and Gynecologists&#xD;
      concludes there is insufficient evidence to render a strong recommendation for either&#xD;
      povidone-iodine or chlorhexidine as the ideal agent for surgical preparation of the vagina&#xD;
      and that further evidence is necessary.&#xD;
&#xD;
      Povidone-iodine solution has been considered the standard for aseptic surgical preparation of&#xD;
      the vagina for decades and is the only solution approved by the FDA for vaginal use. There&#xD;
      are however specific qualities of the solution that suggest it may be less than ideal for use&#xD;
      in the vagina. More contemporary efforts have begun to focus on chlorhexidine as a more ideal&#xD;
      agent for aseptic efforts in surgical preparation of the vagina.&#xD;
&#xD;
      The purpose of our study is to use a randomized controlled trial to determine if&#xD;
      chlorhexidine gluconate surgical preparation maintains a lower rate of contamination to the&#xD;
      surgical field.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The institutional review board recommended the study stop enrollment prior to achieving its&#xD;
    initial sample size for patient safety.&#xD;
  </why_stopped>
  <start_date type="Actual">May 18, 2018</start_date>
  <completion_date type="Actual">January 29, 2020</completion_date>
  <primary_completion_date type="Actual">August 26, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Contamination</measure>
    <time_frame>90 minutes from initial preparation</time_frame>
    <description>Contamination is defined as having &gt;5000 bacteria within a culture</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">94</enrollment>
  <condition>Hysterectomy</condition>
  <arm_group>
    <arm_group_label>Chlorhexidine group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Iodine group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chlorhexidine</intervention_name>
    <description>Chlorhexidine preparation solutions</description>
    <arm_group_label>Chlorhexidine group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iodine</intervention_name>
    <description>Iodine-based preparation solutions</description>
    <arm_group_label>Iodine group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Undergoing total vaginal, laparoscopic assisted vaginal, total laparoscopic, or&#xD;
             robotic-assisted laparoscopic hysterectomy by a physician at Cincinnati Urogynecology&#xD;
             Associates or Tri-State Gynecology Oncology TriHealth Inc.&#xD;
&#xD;
          -  Concomitant procedures such as vaginal vault suspension, suburethral sling,&#xD;
             cystoscopy, enterocele repair, anterior or posterior colporrhaphy, bilateral&#xD;
             salpingectomy or salpingooophorectomy, staging procedures, lymph node sampling and&#xD;
             other indicated procedures will be included&#xD;
&#xD;
          -  English speaking&#xD;
&#xD;
          -  Ability to provide consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unwillingness to participate in the study&#xD;
&#xD;
          -  Non English speaking&#xD;
&#xD;
          -  Patients that do not undergo a hysterectomy&#xD;
&#xD;
          -  Reported allergy to iodine or chlorhexidine preparation solutions&#xD;
&#xD;
          -  Patients undergoing planned debulking surgery for ovarian, fallopian tube or primary&#xD;
             peritoneal cancers&#xD;
&#xD;
          -  Current infection necessitating hysterectomy&#xD;
&#xD;
          -  Active sepsis, pelvic abscess or pelvic inflammatory disease&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Catrina Crisp, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>TriHealth - Cincinnati Urogynecology Associates</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Good Samaritan Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Nugent RP, Krohn MA, Hillier SL. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation. J Clin Microbiol. 1991 Feb;29(2):297-301.</citation>
    <PMID>1706728</PMID>
  </results_reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 22, 2018</study_first_submitted>
  <study_first_submitted_qc>January 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 26, 2018</study_first_posted>
  <results_first_submitted>October 26, 2020</results_first_submitted>
  <results_first_submitted_qc>October 26, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 18, 2020</results_first_posted>
  <last_update_submitted>January 6, 2021</last_update_submitted>
  <last_update_submitted_qc>January 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chlorhexidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 20, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/34/NCT03412734/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>6 patients were excluded (3 - not randomized at the day of surgery; 3 - missing study consent).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Chlorhexidine Group</title>
          <description>Patients randomized to the Chlorhexidine group will undergo pre-surgical vaginal aseptic preparation using 4% Chlorhexidine preparation solutions.</description>
        </group>
        <group group_id="P2">
          <title>Iodine Group</title>
          <description>Those patients randomized to the povidone-iodine group will have their pre-surgical vaginal aseptic preparation performed using 10% povidone-iodine solution.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Incorrect labeling of samples</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Exclusion criteria - patient receiving Flagyl for treatment</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Chlorhexidine Group</title>
          <description>Chlorhexidine: Chlorhexidine preparation solutions</description>
        </group>
        <group group_id="B2">
          <title>Iodine Group</title>
          <description>Iodine: Iodine-based preparation solutions</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="44"/>
            <count group_id="B2" value="41"/>
            <count group_id="B3" value="85"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.6" spread="10.9"/>
                    <measurement group_id="B2" value="62.2" spread="11.6"/>
                    <measurement group_id="B3" value="59.8" spread="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="85"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black/African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Bacterial Vaginosis (BV) positive</title>
          <description>Bacterial Vaginosis was identified through a modified Nugent method (Nugent RP et al. 1991), and Nugent score points was awarded based on three morphotypes:&#xD;
medium to large gram positive rods, small gram negative or variable rods, curved gram negative or variable rods.&#xD;
Each of these morphotypes was assigned a score based on their initial count, and the three morphotypes is then added, and any score &gt;7 is consistent bacterial vaginosis, and a score &lt;3 is normal flora.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Contamination</title>
        <description>Contamination is defined as having &gt;5000 bacteria within a culture</description>
        <time_frame>90 minutes from initial preparation</time_frame>
        <population>Use participants with cultures at 90 minutes</population>
        <group_list>
          <group group_id="O1">
            <title>Chlorhexidine Group</title>
            <description>Chlorhexidine: Chlorhexidine preparation solutions</description>
          </group>
          <group group_id="O2">
            <title>Iodine Group</title>
            <description>Iodine: Iodine-based preparation solutions</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Contamination</title>
          <description>Contamination is defined as having &gt;5000 bacteria within a culture</description>
          <population>Use participants with cultures at 90 minutes</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>We hypothesized that chlorhexidine would have a lower bacterial count compared to iodine. Our sample size was calculated to be 71 patients per arm to detect a 22% difference in cultures defined as contaminated at 90 minutes from surgical preparation.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value is adjusted for baseline BV (Bacterial Vaginosis)</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>10.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.02</ci_lower_limit>
            <ci_upper_limit>37.34</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 week post-op</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Chlorhexidine Group</title>
          <description>Chlorhexidine: Chlorhexidine preparation solutions</description>
        </group>
        <group group_id="E2">
          <title>Iodine Group</title>
          <description>Iodine: Iodine-based preparation solutions</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Catrina Crisp, MD MSc</name_or_title>
      <organization>TriHealth Inc.</organization>
      <phone>513-463-4300</phone>
      <email>Catrina_Crisp@trihealth.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

